

News Release



Sinfonia Biotherapeutics in collaboration with Dr. Giovanna Paolone, Verona University has been awarded a 2-year grant from The Michael J. Fox Foundation for Parkinson's Disease (MJFF) to support preclinical proof of concept studies of a novel combinatorial therapy for treatment of Parkinson's disease associated with mutations in the GBA1 gene, the most common genetic risk factor for developing Parkinson's disease. The novel therapeutic concept combines neurorestorative and neuroprotective biologics in a single therapy and is facilitated by Sinfonia's implantable gene therapy device platform, encapsulated cell biodelivery. "We are very grateful to MJFF for their funding support, and we look forward to continue our successful collaboration with Dr. Paolone's group in developing a clinically meaningful therapy for the benefit of patients suffering from Parkinson's disease", says Dr. Lars Wahlberg, CEO for Sinfonia Biotherapeutics.

For more information, please contact Dr. Lars Wahlberg at LUW@SinfoniaBTx.com